Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Blue LED photobiomodulation in the prevention of radiodermatitis in breast cancer survivors: a clinical trial.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study is to investigate the photobiomodulation (PBM) effects when applying blue LED on the grade and severity of radiodermatitis (RD) and analyze the dermatological quality of life of female breast cancer survivors.
methodThis is a non-randomized, prospective clinical trial, with 53 women diagnosed with breast cancer undergoing radiotherapy (RT). Participants were divided into a control group (CG; n = 27) and an intervention group (IG; n = 26). The intervention consisted of PBM with blue LED (470 nm) before each RT session, with an energy density of 18.6 J/cm
resultsThe RD occurrence was 28% lower (p = 0.039) in the intervention group (n = 11) compared to the CG (n = 19). Dermatological quality of life presents a moderate reduction over time only in the patients in the CG (p = 0.005). This worsening is attributed to increases in the DLQI scores for symptoms and feelings (p = 0.003), daily activities (p = 0.003), and treatment (p = 0.005).
conclusionThe findings suggest that blue LED may be a promising resource to improve the quality of life of patients undergoing RT. IMPLICATIONS FOR CANCER SURVIVORS: Blue LED may be a sound therapeutic strategy in radiodermatitis management, minimizing radiotherapy negative impacts, consequently improving the quality of life.
Indexed as
Identifiers
41454020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.